Jeffrey W. Clark

Massachusetts General Hospital

Full Professor(heuristic)

Pancreatic and Hepatic Oncology Research · Oncology

h-index90

i10-index272

Publications894

Citations41,413

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 94

Supplementary Table S3 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>
2026-06-17
Supplementary Figure S6 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>
2026-06-17
Supplementary Table S2 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>
2026-06-17
Supplementary Figure S2 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>
2026-06-17
Supplementary Figure S1 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>
2026-06-17
Supplementary Figure S3 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>
2026-06-17
Supplementary Table S1 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>
2026-06-17
Supplementary Figure S5 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>
2026-06-17
Data from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>
2026-06-17
Supplementary Figure S4 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>
2026-06-17
Supplementary Table S4 from A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i>, <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, and <i>CHEK2</i>
2026-06-17
Neoadjuvant Stereotactic Body Radiotherapy plus Immune Therapy Favorably Remodels the Hepatocellular Carcinoma Tumor Microenvironment
Clinical Cancer Research · 2026-04-15
Transitioning from neoadjuvant chemoradiation to perioperative chemotherapy for esophageal adenocarcinoma: Impact on margins and pathologic outcomes
JTCVS Open · 2026-04-01
Supplementary Table S2 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025-11-25
Supplementary Table S1 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025-11-25
Supplementary Table S6 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025-11-25
Supplementary Figure S5 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025-11-25
Supplementary Figure S3 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025-11-25
Supplementary Table S3 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025-11-25
Supplementary Table S4 from Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3<sup>+</sup> Cancer Cells in Locally Advanced Pancreatic Cancer
2025-11-25

Open author page on OpenAlex →